Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.

Joseph Shan, vice president of clinical and regulatory affairs at Peregrine commented, "We are very encouraged by the initial results reported today for the full 46 patients enrolled in the bavituximab plus docetaxel Phase II trial. The tumor response data reported in this study exceeded the tumor response data for docetaxel alone that was used as the benchmark for the design of this study. With these positive initial data in hand, we and our expert advisors believe that this combination regimen warrants further clinical evaluation, and we are now assessing possible trial designs for future studies."

The primary objective of the multi-center, open-label Phase Il study is to assess the overall response rate to bavituximab and docetaxel. In this trial's Simon two-stage design, 15 patients were initially enrolled in the study followed by an additional 31 patients after the pre-specified primary efficacy endpoint for expanding the study was met, bringing the total to 46 patients. Initial data from the first set of 15 patients in the study was reported in an oral presentation at the 2009 ASCO Annual Meeting. Recent analysis showed the median progression-free-survival (PFS) of patients enrolled in the initial 15-patient cohort of the study was 7.4 mo
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - Merus Labs International ... MSLI ) is pleased to announce today ... has exercised the over-allotment option to purchase 1,000,550 ... price of C$3.05 per Share granted to the ... public offering which closed on April 30, 2015.  ...
(Date:6/1/2015)... LAKE, N.J. , June 1, 2015 ... Ltd., today announces the immediate appointment of Ivor ... Chief Financial Officer (CFO) and Chief Compliance Officer. In ... responsibility for leading Eisai,s financial operations in the Americas ... audit functions. He will also serve on the company,s ...
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/whgw4t/breast_pumps ) has announced the ... Double Electric and Hospital Grade Breast Pumps) - Global ... 2014 - 2022" report to their offering. ... and Drug Administration. These pumps are designed to mimic ... act as a supplement to breastfeeding. The demand for ...
Breaking Medicine Technology:Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option 2Ivor Macleod Appointed Senior Vice President, Chief Financial Officer and Chief Compliance Officer of Eisai Inc. 2Ivor Macleod Appointed Senior Vice President, Chief Financial Officer and Chief Compliance Officer of Eisai Inc. 3Ivor Macleod Appointed Senior Vice President, Chief Financial Officer and Chief Compliance Officer of Eisai Inc. 4Global Breast Pumps Market (Manual, Single, Double Electric and Hospital Grade Breast Pumps) - Industry Analysis 2015-2022 2
... BOSTON, Nov. 22, 2011 Solos Endoscopy, Inc.,s (OTCPK: ... 3rd Quarter with a Net Profit of $73,895.  Solos ... of debt of $299,082 for the Three Months period ... new consulting agreement result in a reduction of ongoing ...
... Mont., Nov. 22, 2011 Bacterin International Holdings, Inc. ... the development of revolutionary bone graft material and antimicrobial coatings ... MICRO,s 4th Annual Conference on December 8, 2011. The conference ... Bacterin,s chairman and CEO, Guy Cook, is scheduled ...
Cached Medicine Technology:Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2Bacterin to Present at 4th Annual LD MICRO Conference on December 8, 2011 2Bacterin to Present at 4th Annual LD MICRO Conference on December 8, 2011 3
(Date:6/1/2015)... Dallas, Texas (PRWEB) June 01, 2015 ... the brain health landscape on a global level. ... innovative realms, allowing Carrick Brain Centers to broaden their ... of healing. , Broadened horizons are accompanied by a ... June 1, 2015, Carrick Brain Centers will separate itself ...
(Date:6/1/2015)... 2015 The session, entitled “Building the ... vice president of Elektrobit Automotive Americas, senior representatives ... it will be moderated by Andy Gryc of CX3 ... and complexity of in-vehicle software in connected vehicles and ... and how the wider ecosystem can fit into new ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Good360 ... of the Irene W. and C.B. Pennington Foundation, ... organization’s board of directors. Bertman joins Good360 just ... platform this summer. , "Bringing with her many ... I am thrilled that Lori is joining the ...
(Date:6/1/2015)... Palo Alto, Calif. (PRWEB) June 01, 2015 ... weight loss program for children and teens, announced today ... support and coaching channels for kids and teens to eat ... Kurbo users communicated with their coaches via text message and ... advice, and supportive reminders through their in-app chat window. For ...
(Date:6/1/2015)... June 01, 2015 Community Scene ( ... the official launch of its free online platform designed ... 18,000 cities nationwide and globally. , On Community Scene, ... what’s happening in their community – including local news, ... voting polls. Members can choose a home community or ...
Breaking Medicine News(10 mins):Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Lori Bertman Joins Good360 Board of Directors 2Health News:Kurbo, First Mobile Weight Loss Program for Children and Teens, Enhances Coaching with New iOS In-App Chat and Messaging from Coaches 2Health News:Community Scene Launches the Largest Global Social Network for Communities 2
... , WEDNESDAY, May 30 (HealthDay News) -- ... sold online, contains the wrong active ingredients, according to ... also used to treat narcolepsy. The drug, made by ... the United States. The counterfeit versions of Adderall ...
... May 30 (HealthDay News) -- More patients and families are ... if doing do improves the chances of obtaining a donor ... Medical Center in Maywood, Ill., examined 91 Facebook pages that ... and found that 12 percent of the pages reported receiving ...
... Reinberg HealthDay Reporter , WEDNESDAY, May 30 (HealthDay ... during birth and who received whole-body cooling fared better than ... Although rare, the condition can result in brain damage ... by temporarily lowering their body temperature seems to help the ...
... FORT KNOX, Ky., May 30, 2012 Last month, ... around the country attended the American College of Physicians, ... national medical student abstract competitions and share their perspective ... residents earned national awards for their research. "The ...
... 30 (HealthDay News) -- Advancements in human genetic ... are needed to protect against the misuse of people,s ... association offers several policy recommendations, including U.S. government oversight ... anti-discrimination legislation. While discoveries in recent years -- ...
... PHILADELPHIAYounger patients with colorectal cancer were more likely to present ... had better than or equal survival to patients 50 and ... Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, ... Hall A2). The study was led by Edith ...
Cached Medicine News:Health News:FDA Warns of Fake Version of ADHD Drug Adderall 2Health News:More Families Seek Kidney Donations on Facebook 2Health News:'Cooling' Helps Oxygen-Deprived Newborns: Study 2Health News:'Cooling' Helps Oxygen-Deprived Newborns: Study 3Health News:US Army internal medicine residents receive awards from American College of Physicians 2Health News:Brave New World of Genetics Requires Safeguards, Experts Say 2Health News:ASCO: Younger colon cancer patients have worse prognosis at diagnosis, yet better survival 2
... The IEC CL40 and FL40 ... power, safety and versatility to increase ... with a broad array of rotors ... processing and microplate applications, the IEC ...
... IEC CL30 Series from Thermo ... value for your low-speed clinical ... rotor exchange system, user-friendly controls, ... IEC CL30 Series delivers solid ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
... more supple gloving category than standard,latex gloves. ... thin,powder-free gloves on the market today1. Yet ... come to expect from natural rubber latex. ... comes with another huge,advantage it is ...
Medicine Products: